85 related articles for article (PubMed ID: 20815170)
21. Results of the determination of serum markers in patients with malignant melanoma.
Lugović L; Situm M; Buljan M; Poduje S; Sebetić K
Coll Antropol; 2007 Jan; 31 Suppl 1():7-11. PubMed ID: 17469741
[TBL] [Abstract][Full Text] [Related]
22. S100 serum level: a tumour marker for metastatic melanoma.
Bottoni U; Izzo P; Richetta A; Mannooranparampil TJ; Devirgiliis V; Del Giudice M; Reale MG; Frati L; Calvieri S
Melanoma Res; 2003 Aug; 13(4):427-9. PubMed ID: 12883371
[No Abstract] [Full Text] [Related]
23. Clinical value of serum TAG-72 as a tumor marker for pancreatic carcinoma. Comparison with CA 19-9.
Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
Int J Pancreatol; 1994 Jun; 15(3):171-7. PubMed ID: 7930777
[TBL] [Abstract][Full Text] [Related]
24. Immune-related biomarkers for diagnosis/prognosis and therapy monitoring of cutaneous melanoma.
Neagu M; Constantin C; Tanase C
Expert Rev Mol Diagn; 2010 Oct; 10(7):897-919. PubMed ID: 20964610
[TBL] [Abstract][Full Text] [Related]
25. [Evaluation of RCAS1 as serum tumor marker for pancreatic cancer].
Yang YC; Zhao YP; Liao Q; Zhang TP; Hu Y; Dai MH
Zhonghua Wai Ke Za Zhi; 2009 Jul; 47(13):999-1001. PubMed ID: 19957811
[TBL] [Abstract][Full Text] [Related]
26. Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B.
Paschen A; Sucker A; Hill B; Moll I; Zapatka M; Nguyen XD; Sim GC; Gutmann I; Hassel J; Becker JC; Steinle A; Schadendorf D; Ugurel S
Clin Cancer Res; 2009 Aug; 15(16):5208-15. PubMed ID: 19671853
[TBL] [Abstract][Full Text] [Related]
27. Significance of RCAS1 antigen in hepatocellular, cholangiocellular and pancreatic carcinomas.
Enjoji M; Nakashima M; Yamaguchi K; Kotoh K; Nakamuta M
J Gastroenterol Hepatol; 2005 Aug; 20(8):1143-8. PubMed ID: 16048560
[TBL] [Abstract][Full Text] [Related]
28. Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma.
Abraha HD; Fuller LC; Du Vivier AW; Higgins EM; Sherwood RA
Br J Dermatol; 1997 Sep; 137(3):381-5. PubMed ID: 9349333
[TBL] [Abstract][Full Text] [Related]
29. Circulating intercellular adhesion molecule 1 as a marker of disease progression in cutaneous melanoma.
Altomonte M; Colizzi F; Esposito G; Maio M
N Engl J Med; 1992 Sep; 327(13):959. PubMed ID: 1355268
[No Abstract] [Full Text] [Related]
30. [Serum sialic acid bound to lipoproteins. Its contribution to the diagnosis and follow-up of melanoma].
Sánchez Conejo-Mir J; Sotillo Gago I; Camacho F; Iglesias Huertas R
Med Cutan Ibero Lat Am; 1990; 18(4):219-23. PubMed ID: 2077306
[TBL] [Abstract][Full Text] [Related]
31. Serum zinc levels are increased in melanoma patients.
Ros-Bullón MR; Sánchez-Pedreño P; Martínez-Liarte JH
Melanoma Res; 1998 Jun; 8(3):273-7. PubMed ID: 9664150
[TBL] [Abstract][Full Text] [Related]
32. Cluster analysis of serum proteins in malignant cutaneous melanoma: search for disease markers.
Ragazzi E; Vogliardi S; Allegri G; Costa CV; Lise M; Rossi CR; Seraglia R; Traldi P
Rapid Commun Mass Spectrom; 2003; 17(13):1511-5. PubMed ID: 12820221
[No Abstract] [Full Text] [Related]
33. [S-100B and MIA (melanoma inhibiting activity) serum proteins: a prospective study of their value as melanoma progression markers].
Dornier C; Dousset B; Legras B; Barbaud A; Schmutz JL
Ann Dermatol Venereol; 2002 May; 129(5 Pt 1):739-40. PubMed ID: 12124520
[No Abstract] [Full Text] [Related]
34. Synchronous metastatic malignant melanoma and primary adenocarcinoma in the colon.
Chiu HH; Liu YW; Huang CC
Gastrointest Endosc; 2007 Sep; 66(3):600; discussion 601. PubMed ID: 17681502
[No Abstract] [Full Text] [Related]
35. [Small intestinal mucin antigen (SIMA)].
Endo T; Akashi H; Arimura Y; Shinomura Y
Nihon Rinsho; 2010 Jul; 68 Suppl 7():772-4. PubMed ID: 20960870
[No Abstract] [Full Text] [Related]
36. [Tumor markers for pancreatic and biliary tract cancer].
Takezako Y; Okusaka T; Ueno H; Ikeda M; Morizane C; Najima M
Gan To Kagaku Ryoho; 2004 Sep; 31(9):1443-6. PubMed ID: 15446574
[TBL] [Abstract][Full Text] [Related]
37. Serum TA90 antigen-antibody complex as a surrogate marker for the efficacy of a polyvalent allogeneic whole-cell vaccine (CancerVax) in melanoma.
Tsioulias GJ; Gupta RK; Tisman G; Hsueh EC; Essner R; Wanek LA; Morton DL
Ann Surg Oncol; 2001 Apr; 8(3):198-203. PubMed ID: 11314934
[TBL] [Abstract][Full Text] [Related]
38. Does endogenous immune response determine the outcome of surgical therapy for metastatic melanoma?
Hsueh EC; Gupta RK; Yee R; Leopoldo ZC; Qi K; Morton DL
Ann Surg Oncol; 2000 Apr; 7(3):232-8. PubMed ID: 10791855
[TBL] [Abstract][Full Text] [Related]
39. [Clinical significance of TAG-72 assay as a tumor marker].
Motoo Y; Sawabu N
Nihon Rinsho; 1990 Feb; 48 Suppl():1064-7. PubMed ID: 2355505
[No Abstract] [Full Text] [Related]
40. [Small intestinal mucin antigen (SIMA)].
Endo T; Sugawara N; Imai K
Nihon Rinsho; 2005 Aug; 63 Suppl 8():730-2. PubMed ID: 16149625
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
